JAK inhibitors attenuate hyperactivation of nonswitched memory B cells in rheumatoid arthritis patients in remission
Authors' conclusion
RA patients present different B-cell subpopulations, in which the frequency of NSMB cells is negatively associated with disease activity. However, treatment with JAKis can inhibit activation of NSMB cells, restore the balance of kinase phosphorylation, and facilitate disease remission in RA patients.
Study context
- Population
- Adult rheumatoid arthritis (RA) patients, including new-onset untreated patients and patients treated with Janus kinase inhibitors (JAKis)31 RA patients treated with JAKis
- Participants
- 58 vs 23
- Comparison
- RA patients vs healthy controls
- RAn = 58
- Healthy controlsn = 23reference
- Outcome
- Distribution and activation of peripheral B-cell subpopulations and their correlation with disease remission
Methodological details24-month follow-up, flow cytometry
- 24-month follow-up
- Flow cytometry
Main finding
As reported in the abstract
B-cell subpopulations in new-onset untreated RA vs healthy controls
- Nonswitched memory B (NSMB) cell frequency significantly lower in new-onset untreated RA than in healthy controls
- CD40, CD80, CD95, CD21low and pAKT expression significantly increased in NSMB cells
- NSMB cell number correlated negatively with DAS28-ESR and IgG and IgA levels
- CD80, CD95 and CD21low expression on NSMB cells correlated positively with DAS28-ESR and IgG and IgA levels
Further findings
After JAKi treatment, RA patients in remission
- Serum IgG concentration significantly decreased
- CD40, CD95 and pAKT levels in NSMB cells significantly decreased
Original publication
JAK inhibitors attenuate hyperactivation of nonswitched memory B cells in rheumatoid arthritis patients in remission. Arthritis Res Ther. Published 17 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →